Compare ACRS & HVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | HVT |
|---|---|---|
| Founded | 2012 | 1885 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 435.8M |
| IPO Year | 2015 | 1994 |
| Metric | ACRS | HVT |
|---|---|---|
| Price | $3.77 | $29.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $10.18 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 82.1K |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 4.42% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $1,683,000.00 | ★ $758,995,000.00 |
| Revenue This Year | N/A | $5.99 |
| Revenue Next Year | N/A | $7.90 |
| P/E Ratio | ★ N/A | $38.75 |
| Revenue Growth | N/A | ★ 4.99 |
| 52 Week Low | $2.10 | $20.06 |
| 52 Week High | $6.60 | $29.84 |
| Indicator | ACRS | HVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 64.20 |
| Support Level | $3.18 | $26.93 |
| Resistance Level | $3.86 | $29.83 |
| Average True Range (ATR) | 0.31 | 0.58 |
| MACD | 0.07 | 0.19 |
| Stochastic Oscillator | 54.05 | 81.79 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of revenue from its upholstery products and, secondarily, from bedroom furniture.